Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | BCR | P11274 | 2/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.37 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12970641 | 0.83 | SLC6A2 (0.46) | SLC6A2SLC6A4CACNA1BMAPK1PARP1 | |
| SCHEMBL3784025 | 0.83 | ALDH1A1 (0.45) | SLC6A2SLC6A4KMT2ACHEK1SCN9A | |
| SCHEMBL30540337 | 0.83 | SLC6A2 (0.46) | SLC6A2SLC6A4MAPK1PARP1CHEK2 | |
| SCHEMBL3641624 | 0.83 | APP (0.50) | SLC6A2SLC6A4MAPK1PARP1KMT2A | |
| SCHEMBL23081287 | 0.81 | PARP1 (0.45) | SLC6A2SLC6A4CACNA1BMAPK1PARP1 | |
| SCHEMBL13733032 | 0.81 | SLC6A2 (0.45) | SLC6A2SLC6A4CACNA1BMAPK1PARP1 | |
| SCHEMBL4638596 | 0.81 | AVPR2 (0.47) | KMT2AL3MBTL1PDK2ABL1ALPL | |
| SCHEMBL4441995 | 0.81 | DGAT1 (0.54) | PARP1CHEK1ALPLSCN9AEPHX2 | |
| SCHEMBL20541755 | 0.81 | SCN9A (0.41) | PARP1KMT2ACHEK1SCN9AALDH1A1 | |
| SCHEMBL3778656 | 0.81 | MAP2K1 (0.40) | SLC6A2SLC6A4CHEK1SCN9AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | claimed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | claimed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | claimed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | claimed |
| CN-107847600-B | Combination therapy of anti-CD 20 antibodies with Bcl-2 inhibitors and MDM2 inhibitors | 豪夫迈·罗氏有限公司 | 2021-09-03 | — | — | CN | disclosed |
| EP-3302549-B1 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BCL-2 INHIBITOR AND A MDM2 INHIBITOR | HOFFMANN LA ROCHE (CH) | 2019-07-03 | — | — | EP | disclosed |
| EP-3302549-A1 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BCL-2 INHIBITOR AND A MDM2 INHIBITOR | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| US-9657351-B2 | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist | HOFFMAN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| WO-2016188935-A1 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BCL-2 INHIBITOR AND A MDM2 INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-01 | — | — | WO | disclosed |
| US-20160347852-A1 | Combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor | HOFFMANN-LA ROCHE INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150211073-A1 | MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2015-07-30 | — | — | US | disclosed |
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | SLC6A2 4594/4885SLC6A4 4449/4885CACNA1B 3367/4885 |
| US-20150211073-A1 | MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST | MDM2, TP53, TP53BP1 | SLC6A2 4572/4885SLC6A4 4095/4885CACNA1B 4703/4885 |
| US-20160347852-A1 | Combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor | BCL2L1, MCL1, CD22 | SLC6A2 4499/4885SLC6A4 4748/4885CACNA1B 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.